for educational and safety purposes
Every compound in the sci-wiki that affects neurosteroidogenesis; the ones you can source are floated to the front, then the reference-only entries. Tap any for the full entry, mechanism, and outlets.
5 sourced · 24 reference
Pregnenolone (3β-hydroxypregn-5-en-20-one) is an endogenous neurosteroid and the first steroid synthesized from cholesterol, making it the obligatory precursor of every other steroid hormone, including progesterone, dehydroepiandrosterone (DHEA), cortisol, the sex steroids, and the neuroactive metabolites allopregnanolone and pregnenolone sulfate. Once regarded as a metabolically inert intermediate, it is now recognized as a signaling molecule in its own right, most notably as an endogenous negative allosteric modulator of the type-1 cannabinoid receptor (CB1, the principal brain receptor for THC) and as a ligand for microtubule-associated protein 2 (MAP2, a neuronal cytoskeletal scaffolding protein), through which it promotes microtubule assembly and neurite outgrowth. Synthesized de novo in the brain by neurons and glia, it is investigated as an adjunctive treatment for schizophrenia, mood disorders, and cannabis-related conditions, and is sold over the counter as a nootropic and hormonal supplement.
Dehydroepiandrosterone (DHEA) is an endogenous androstane neurosteroid and the most abundant circulating steroid hormone in humans, secreted chiefly by the adrenal cortex and also synthesized de novo within the central nervous system. It functions primarily as a precursor to androgens and estrogens, yet exerts direct actions on the brain by acting as an agonist at the sigma-1 receptor (an endoplasmic reticulum chaperone protein that shapes calcium and neurotrophic signaling), as a positive modulator of NMDA receptor (the principal excitatory glutamate ion channel involved in learning) signaling, and, chiefly as its sulfate ester DHEAS, as a negative allosteric modulator of the GABA-A receptor (the brain's main inhibitory ion channel). DHEA additionally behaves as a functional anti-glucocorticoid, buffering the neurotoxic effects of cortisol, and shows neuroprotective and mood-related activity in preclinical and clinical studies. Circulating concentrations peak in early adulthood and decline markedly with age, a phenomenon termed adrenopause that has driven its widespread use as an over-the-counter supplement.
Etifoxine (brand name Stresam; also called etafenoxine) is a benzoxazine anxiolytic (an anti-anxiety drug from a chemical family unrelated to the benzodiazepines like Valium). It has been prescribed for the anxious, tense, physical side of stress mainly in France and a handful of other countries since the late 1970s, and it is not approved by the US FDA. What makes it interesting is a dual mechanism: it calms the brain both by directly tuning up GABA-A receptors and by nudging the body to make more of its own calming neurosteroids. In head-to-head trials it eased anxiety comparably to some benzodiazepines while causing less sedation, less memory and psychomotor impairment, and little rebound or dependence when stopped. It has also been explored beyond anxiety for helping injured peripheral nerves heal and for damping neuroinflammation (inflammation inside nervous tissue). The important caveat is safety: rare but serious liver injury and severe skin reactions have been reported.
Pregnanolone (3α-hydroxy-5β-pregnan-20-one, also written 3α,5β-tetrahydroprogesterone) is an endogenous neurosteroid, meaning a steroid that acts rapidly on neuronal ion channels rather than through classical intracellular hormone receptors, formed as a reduced metabolite of progesterone. It is the 5β epimer of allopregnanolone and a potent positive allosteric modulator of the GABA-A receptor (the pentameric chloride channel that carries most fast inhibitory signalling in the brain), giving it sedative, anxiolytic, anticonvulsant and anaesthetic properties. Under the International Nonproprietary Name eltanolone it was developed in the 1990s as an intravenous general anaesthetic, formulated in a soybean-oil emulsion after earlier castor-oil-solubilised steroid anaesthetics proved allergenic; smooth induction and cardiovascular stability were offset by slow recovery and skin reactions, and it was never marketed. Its sulfate and synthetic glutamate esters are studied separately as use-dependent inhibitors of the NMDA receptor, an excitatory glutamate channel implicated in excitotoxicity and neuroprotection.
Progesterone (P4; pregn-4-ene-3,20-dione) is an endogenous pregnane steroid hormone best known for its reproductive roles and is the prototypical neuroactive precursor within the neurosteroid system. Although the parent hormone signals principally through classical nuclear progesterone receptors and through membrane-associated receptors such as PGRMC1 and the mPR/PAQR family, most of its rapid effects on neuronal excitability arise only after sequential metabolism to 5-alpha-dihydroprogesterone and then to allopregnanolone, one of the most potent endogenous positive allosteric modulators of the GABA-A receptor (the brain's principal inhibitory chloride channel). Progesterone and its metabolites are synthesized within the nervous system itself, where they regulate myelination, neuronal survival, neuroinflammation, and inhibitory tone. It has been studied extensively as a neuroprotective agent, with strong preclinical support but negative large-scale human trials in acute traumatic brain injury.
24(S)-Hydroxycholesterol (historically named cerebrosterol) is an endogenous oxysterol (an oxygenated derivative of cholesterol) generated almost exclusively in neurons by the enzyme cholesterol 24-hydroxylase (CYP46A1). It is the principal chemical route by which the brain, which cannot degrade cholesterol, exports its surplus; because the added hydroxyl group at carbon 24 allows the molecule to cross the blood-brain barrier (the selective interface between blood and brain tissue), plasma levels of 24(S)-hydroxycholesterol serve as an accessible marker of brain cholesterol turnover and neuronal mass. Beyond its housekeeping role, it is a bona fide neurosteroid; at physiological concentrations it acts as a potent positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors (a class of glutamate-gated ion channels central to learning and memory) and as an agonist of liver X receptors (LXR, nuclear receptors that govern lipid handling). Its pharmacology inspired the synthetic analog dalzanemdor (SAGE-718), an NMDA receptor positive allosteric modulator developed for cognitive impairment.
3α-Androstanediol (5α-androstane-3α,17β-diol) is an endogenous neurosteroid formed as the terminal 3α-reduced metabolite of dihydrotestosterone (DHT, the most potent natural androgen). Despite its androgenic origin it binds the androgen receptor only weakly; its defining pharmacology is potent positive allosteric modulation of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), which produces anxiolytic (anxiety-reducing) and anticonvulsant (seizure-suppressing) effects in animal models. It is widely regarded as the androgenic counterpart of allopregnanolone (the analogous progesterone-derived neurosteroid), and is proposed to mediate much of the influence that testosterone exerts on seizure threshold, anxiety, and mood in males. It additionally acts as a ligand of estrogen receptor beta (ERβ), which may underlie some of its cognitive and neuroprotective actions.
5α-Dihydroprogesterone (5α-DHP) is an endogenous neurosteroid and progestogen formed when the enzyme 5α-reductase reduces progesterone at the A-ring of the steroid nucleus, yielding 5α-pregnane-3,20-dione. It occupies the committed first step of the principal neurosteroid pathway, standing between progesterone and allopregnanolone (its 3α-hydroxylated metabolite and one of the most potent naturally occurring positive modulators of the GABA-A receptor, the brain's main inhibitory ion channel). Unlike allopregnanolone, 5α-DHP is itself a high-affinity agonist of the classical (nuclear) progesterone receptor, driving progesterone-responsive gene transcription; in horses it is a fully biopotent progesterone receptor agonist that sustains the second half of pregnancy after circulating progesterone becomes undetectable. It is synthesized in situ within neurons and glia of the central and peripheral nervous systems, where its production rises after nerve injury and falls under chronic stress.
Allopregnanolone (chemically 3-alpha-hydroxy-5-alpha-pregnan-20-one, also known as 3-alpha,5-alpha-tetrahydroprogesterone or 3-alpha,5-alpha-THP) is an endogenous neurosteroid synthesized in the brain, adrenal glands and gonads as a downstream metabolite of the hormone progesterone. It is the prototypical inhibitory neuroactive steroid and one of the most potent known positive allosteric modulators (molecules that amplify a receptor's response to its natural transmitter) of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), acting at both synaptic receptors and extrasynaptic delta-subunit-containing receptors. The pharmaceutical formulation of this exact molecule, brexanolone (trade name Zulresso), became in 2019 the first drug ever approved by the United States Food and Drug Administration specifically for postpartum depression, and its orally active analog zuranolone followed in 2023. Beyond its rapid actions on inhibitory neurotransmission, allopregnanolone participates in the stress response, ovarian-cycle and pregnancy physiology, seizure regulation and, as more recently characterized, the suppression of innate-immune inflammatory signaling.
Allotetrahydrocorticosterone (3α,5α-tetrahydrocorticosterone, or allo-THB) is an endogenous neurosteroid generated by sequential 5α-reduction and 3α-hydroxylation of the adrenal glucocorticoid corticosterone. It is the corticosterone-derived structural counterpart of THDOC (which is formed the same way from deoxycorticosterone) and behaves as a positive allosteric modulator (an enhancer that boosts a receptor's response without activating it directly) of the GABA-A receptor (the brain's principal inhibitory chloride ion channel); the additional 11β-hydroxyl group it carries, however, makes it a considerably weaker potentiator than THDOC or allopregnanolone. Beyond GABA-A it shows an unusually broad ion-channel profile, inhibiting glycine receptors (a second inhibitory chloride channel, prominent in the brainstem and spinal cord) and N-type calcium channels (presynaptic channels that gate neurotransmitter release), opening large-conductance calcium-activated potassium channels (BK or Maxi-K channels) in sensory nerves, and retaining residual glucocorticoid-receptor agonism. Clinically it appears mainly as a minor urinary corticosteroid metabolite that indexes 5α-reductase activity in steroid profiling.
Androstadienol (androsta-5,16-dien-3β-ol) is an endogenous C19 (nineteen-carbon) delta-5,16 steroid alcohol that functions as the committed biosynthetic precursor of the 16-androstene family of chemosensory steroids, including androstadienone, androstenone and androstenol. It is formed in the gonads (and, at lower levels, in other steroidogenic tissue) from pregnenolone by a minor side activity of the enzyme CYP17A1 (cytochrome P450 17A1, the same enzyme that makes dehydroepiandrosterone); this activity is historically called andien-beta synthase or 16-ene-synthase. Because its downstream metabolites are the putative human axillary chemosignals and the compounds responsible for boar taint, androstadienol occupies the upstream branch point of a pathway of considerable interest to olfactory neuroscience and reproductive endocrinology. It should not be confused with fasedienol (aloradine), a synthetic 4,16-dien-3β-ol nasal drug; androstadienol is the naturally occurring 5,16-diene.
Androstadienone (androsta-4,16-dien-3-one) is an endogenous volatile C19 16-androstene steroid found in male axillary sweat, semen, saliva and plasma, and the most intensively studied candidate human chemosignal or "pheromone." It is not a classical ion-channel neurosteroid; its central actions are triggered peripherally through the main olfactory epithelium, where the odorant receptor OR7D4 (a G-protein-coupled receptor) is the principal transducer and its genetic variation explains much of the wide person-to-person difference in whether the compound smells sweaty, urinous, sweet or nothing at all. Controlled exposure has been reported to modulate mood, sustained attention, salivary cortisol, autonomic tone and hypothalamic and frontolimbic activity, often in a sex-dependent and strongly context-dependent way. The evidence base is large but contested; effect sizes are small and several findings have failed to replicate, so the compound remains a putative rather than a proven pheromone.
Androstenediol (androst-5-ene-3β,17β-diol, commonly abbreviated 5-androstenediol or 5-AED) is an endogenous Δ5 androstane steroid formed as a direct metabolite of dehydroepiandrosterone (DHEA, the most abundant circulating adrenal steroid). It sits at a branch point in steroidogenesis, functioning both as a weak, ERβ-preferring estrogen (a steroid that activates the estrogen receptor) and as a prohormone that can be converted onward to testosterone. Its most distinctive documented activity is immunomodulatory and hematopoietic; under the development code Neumune it was investigated as a radiation countermeasure that accelerates recovery of white blood cells and platelets after whole-body irradiation. Its inclusion in the neurosteroid grouping is one of exhaustiveness, since unlike allopregnanolone it has only a marginal classic neurosteroid profile at the GABA-A and NMDA receptors, and its central effects are attributed mainly to estrogen receptor beta signaling.
Androstenol (5-alpha-androst-16-en-3-alpha-ol, with a 3-beta epimer) is an endogenous 16-androstene steroid (a C19 steroid that lacks the C-17 oxygen of typical androgens) and a putative human chemosignal. It is synthesized alongside testosterone in the testis, secreted in axillary (underarm) sweat, and also occurs as a major aroma component of truffles, where its volatile, musky odor is biologically active. Its documented neuroactivity in humans is chemosensory; smelling androstenol has been reported to shift self-rated mood and social judgments in some experiments and to activate the anterior hypothalamus in women, although rigorous reviews consider the evidence for a true human pheromone effect weak and inconsistent. It is grouped with the neurosteroids because it is a steroid with measurable central chemosensory and neuroendocrine effects, not because a defined ion-channel mechanism has been established.
Androstenone (5alpha-androst-16-en-3-one) is an endogenous 16-androstene steroid and the archetypal mammalian putative pheromone, best known as the principal component of "boar taint" (the urinous off-odor of intact male pork) and as a minor constituent of human axillary sweat and saliva. Unlike the classic anesthetic neurosteroids that act on the GABA-A receptor (the brain's main inhibitory ion channel), androstenone is a chemosensory neuroactive steroid; its dominant known target in the nervous system is the olfactory receptor OR7D4, expressed on sensory neurons of the nasal epithelium. Its perception is one of the most strikingly variable in human sensory biology, ranging from a strong urinous or sweaty odor, to a faint sweet or floral note, to complete inability to detect it, and this variation is largely explained by coding polymorphisms in the OR7D4 gene. The compound is a foundational model odorant for the molecular genetics of smell, for specific anosmia, and for olfactory plasticity.
Androsterone (3α-hydroxy-5α-androstan-17-one) is an endogenous androstane neurosteroid (a steroid synthesized or acting within the nervous system) and a peripheral metabolite of testosterone and dehydroepiandrosterone. Like its pregnane counterpart allopregnanolone, it acts as a positive allosteric modulator (an agent that enhances a receptor's response to its natural transmitter) of the GABA-A receptor (the brain's principal inhibitory ion channel), producing barbiturate-like potentiation of inhibitory neurotransmission. In rodent studies it raises seizure threshold across multiple models and is regarded as an endogenous modulator of neuronal excitability; because native androsterone is rapidly conjugated and orally poorly available, a prodrug (an inactive precursor that converts to the active drug in the body) has been investigated for epilepsy.
Deoxycorticosterone (11-deoxycorticosterone, 21-hydroxyprogesterone; also called cortexone or desoxycortone) is an endogenous steroid hormone made by the adrenal cortex that functions both as a mineralocorticoid and as the metabolic precursor to a potent neurosteroid. Acting through the mineralocorticoid receptor (a ligand-activated transcription factor that governs sodium and water balance), it promotes renal salt retention with an affinity close to that of aldosterone. Its principal relevance to neuropharmacology is as the parent compound of 3-alpha,5-alpha-tetrahydrodeoxycorticosterone (THDOC), a positive allosteric modulator of the GABA-A receptor (the brain's main inhibitory chloride channel) that is released during stress and shapes seizure threshold, anxiety, and hypothalamic-pituitary-adrenal (HPA) axis activity. Deoxycorticosterone should not be confused with the psychedelic amphetamine also abbreviated DOC (2,5-dimethoxy-4-chloroamphetamine), which is an entirely unrelated compound.
DHEA sulfate (DHEAS) is the 3-beta sulfate ester of dehydroepiandrosterone and the most abundant circulating steroid in the human body, present in plasma at concentrations roughly a thousandfold higher than unconjugated DHEA. Synthesized principally in the zona reticularis of the adrenal cortex, it functions as a stable, long-lived reservoir that is interconverted with DHEA and supplies a precursor pool for downstream androgens and estrogens. Within the nervous system it is classified as a neurosteroid (a steroid synthesized in or acting directly upon nervous tissue); it acts as an agonist at the sigma-1 receptor (an intracellular chaperone protein), a positive modulator of the NMDA receptor (a glutamate-gated excitatory ion channel), and a negative allosteric modulator of the GABA-A receptor (the brain's principal inhibitory ion channel), giving it a net excitatory, pro-cognitive neuromodulatory profile. Circulating concentrations fall markedly with age, a decline termed adrenopause that has made DHEAS a widely studied biomarker of adrenal function, cognitive aging, and longevity.
Emapunil (developmental codes XBD-173 and AC-5216) is an investigational anxiolytic that acts as a selective, high-affinity agonist of the 18-kDa translocator protein (TSPO), a mitochondrial cholesterol-transport protein once known as the peripheral or mitochondrial benzodiazepine receptor. Rather than binding the central benzodiazepine site itself, emapunil stimulates the brain's own synthesis of neurosteroids, most notably allopregnanolone, which then potentiate GABA-A receptors (the brain's main inhibitory chloride channels) to produce anxiolysis. In a landmark 2009 human panic-provocation study it reduced induced anxiety without the sedation, tolerance, or withdrawal that characterise benzodiazepines. It reached Phase 2 clinical evaluation before development was discontinued, and it remains a widely cited proof of concept for neurosteroid-based anxiolysis.
Epiandrosterone (3β-hydroxy-5α-androstan-17-one; also called isoandrosterone) is an endogenous 5-alpha-reduced steroid formed from dehydroepiandrosterone (DHEA) and androstenedione, and it is the 3-beta-hydroxyl epimer of androsterone. It circulates in humans predominantly as its sulfate ester and functions as a weak neurosteroid (a steroid that acts on neuronal receptors rather than classical nuclear hormone receptors), producing only mild modulation of the GABA-A receptor (the brain's principal inhibitory chloride ion channel) while inhibiting glycine receptors (another inhibitory ligand-gated channel concentrated in the spinal cord and brainstem). Beyond the nervous system it is a well-characterized uncompetitive inhibitor of glucose-6-phosphate dehydrogenase (G6PD, the rate-limiting enzyme of the pentose phosphate pathway) and a recognized urinary marker of 5-alpha-reductase activity. Because it can be metabolized toward dihydrotestosterone (DHT, the most potent natural androgen), it is also sold over the counter as a non-methylated androgen prohormone.
Epipregnanolone (3beta-hydroxy-5beta-pregnan-20-one) is an endogenous neurosteroid and the fourth stereoisomer of tetrahydroprogesterone, distinguished from allopregnanolone (3alpha,5alpha), pregnanolone (3alpha,5beta), and sepranolone (3beta,5alpha) by its combined 3beta-hydroxyl group and 5beta (cis) ring fusion. It is a ring A-reduced metabolite of progesterone that, unlike the sedative potentiators allopregnanolone and pregnanolone, was classically characterized as a selective antagonist at the neurosteroid modulatory site of the GABA-A receptor (the brain's principal inhibitory ion channel), blocking their potentiation without altering the response to GABA itself. Its 3-sulfate ester is a negative allosteric modulator of the NMDA receptor (a glutamate-gated excitatory channel), and the parent steroid is also a potent blocker of CaV3.2 T-type calcium channels, giving it a profile that is unusually distinct from its potentiating sister isomers. Present at low concentrations in human plasma, especially around parturition, and producible by human gut bacteria, epipregnanolone is studied primarily as a pharmacological tool and a scaffold for neurosteroid drug design rather than as a therapeutic or supplement.
Estratetraenol (estra-1,3,5(10),16-tetraen-3-ol) is an endogenous estrane steroid (a C18 steroid built on the same carbon skeleton as the estrogens) first isolated from the urine of pregnant women in 1968. It carries an aromatic A-ring like the classical estrogens but lacks the oxygen at carbon 17, which leaves it essentially devoid of conventional estrogenic hormone activity. It is best known as a putative human chemosignal (a chemical thought to carry social information between individuals), where it is treated as the female-associated counterpart to the male-associated steroid androstadienone. A body of psychophysical and neuroimaging work reports that trace, near-odorless exposure to estratetraenol can bias perception, mood, and physiological arousal in a sexually dimorphic manner, although independent replications have been mixed and its status as a true pheromone remains contested.
Etiocholanolone (3α-hydroxy-5β-androstan-17-one) is an endogenous androstane neurosteroid formed as a major hepatic metabolite of testosterone and androstenedione. It is the 5-beta epimer of androsterone and acts as a positive allosteric modulator (a compound that amplifies a receptor's response to its own natural ligand) of the GABA-A receptor (the brain's principal inhibitory chloride channel), where it enhances inhibitory neurotransmission and produces anticonvulsant effects in animal seizure models. Etiocholanolone is equally notable in classical human physiology as one of the first identified endogenous pyrogens; injection of the unconjugated steroid reliably produces fever by prompting leukocytes to release interleukin-1. It possesses negligible androgenic activity and circulates largely as biologically inactive glucuronide and sulfate conjugates.
Itruvone (development code PH-10, also written PH10) is an investigational synthetic neuroactive steroid of the pherine class being studied as a rapid-acting intranasal treatment for major depressive disorder. Chemically a pregnane steroid (pregn-4-en-20-yn-3-one, an ethynyl-substituted steroid backbone), it is delivered as a low-dose aqueous nasal spray and is proposed to act through a novel chemosensory mechanism, engaging receptors in the nasal lining that signal to limbic (emotion-processing) brain circuits without meaningful systemic absorption. In an early exploratory randomized trial it separated from placebo on standard depression rating scales within the first week of treatment and showed a benign side-effect profile, though its evidence base remains limited to small studies. It is developed by Vistagen and is frequently confused with its sibling pherine fasedienol (PH94B), which targets social anxiety disorder instead.
MAP4343 (3β-methoxypregnenolone) is a synthetic derivative of the endogenous neurosteroid pregnenolone in which the 3β-hydroxyl group is replaced by a methyl ether, developed by the French steroid pharmacologist Étienne-Émile Baulieu and the biotechnology company Mapreg. Unlike classical neurosteroids that modulate ligand-gated ion channels, MAP4343 acts on microtubule-associated protein 2 (MAP2; a structural protein that governs the assembly and stability of neuronal microtubules), where it promotes tubulin polymerization and restores microtubule dynamics. It has been investigated as a novel, mechanistically distinct antidepressant and anti-addiction candidate, showing rapid and durable antidepressant-like effects in rodent and tree shrew stress models and having advanced into early clinical development. As of the mid-2020s it remains an investigational agent without regulatory approval.
Pregnenolone sulfate (PregS) is an endogenous excitatory neurosteroid (a steroid synthesized in and acting upon the nervous system) formed by sulfation of pregnenolone at its 3beta-hydroxyl group. It is among the most intensively studied neurosteroids in ion-channel pharmacology, acting simultaneously as a positive allosteric modulator of N-methyl-D-aspartate (NMDA) receptors that contain GluN2A or GluN2B subunits (the principal glutamate-gated channels underlying synaptic plasticity), a negative allosteric modulator of GABA-A receptors (the brain's main inhibitory chloride channels), a low-affinity agonist of the sigma-1 receptor (an intracellular chaperone protein) and the prototypical agonist of the TRPM3 cation channel. Through these convergent actions it enhances glutamatergic transmission, hippocampal acetylcholine release, long-term potentiation and memory consolidation in animal models, which underlies its reputation as a pro-cognitive neurosteroid. Its physiological concentrations, and even its unambiguous presence in mammalian brain, remain debated, so much of the evidence base derives from experimental administration rather than demonstrated endogenous signaling.
Dalzanemdor (SAGE-718) is a first-in-class, orally administered synthetic neuroactive steroid developed by Sage Therapeutics that acts as a positive allosteric modulator (a molecule that boosts a receptor's response without occupying its main agonist site) of the N-methyl-D-aspartate (NMDA) receptor, the principal excitatory glutamate-gated ion channel of the brain. It is a structural analog of the endogenous brain oxysterol 24(S)-hydroxycholesterol (24(S)-HC), a cholesterol metabolite that the same laboratory identified as a naturally occurring NMDA receptor PAM. The compound was advanced into clinical development for cognitive impairment associated with disorders thought to involve NMDA receptor hypofunction, including Huntington's disease, Parkinson's disease, and Alzheimer's disease. Its Phase 2 program, most notably the DIMENSION study in Huntington's disease, largely failed to meet primary cognitive endpoints during 2024 and 2025, after which Sage Therapeutics terminated the open-label Phase 3 PURVIEW study.
Sepranolone (isoallopregnanolone; 3beta-hydroxy-5alpha-pregnan-20-one) is an endogenous pregnane neurosteroid that is the 3beta-epimer of allopregnanolone, differing only in the spatial orientation of a single hydroxyl group at carbon 3. Whereas allopregnanolone is one of the most potent known positive modulators of the GABA-A receptor (the brain's principal inhibitory chloride ion channel), isoallopregnanolone possesses no intrinsic modulatory activity of its own and instead acts as a selective functional antagonist that reverses allopregnanolone's enhancement of GABA-A signalling without touching the benzodiazepine site, the barbiturate site, or the basal GABA response. Under the development name UC1010 it has been advanced by Asarina Pharma as a subcutaneously administered candidate for premenstrual dysphoric disorder (PMDD) and related menstrually entrained and compulsive conditions, reaching Phase 2 clinical testing. It represents the prototype of a drug class termed GAMSA (GABA-A receptor modulating steroid antagonists).
THDOC (3-alpha,5-alpha-tetrahydrodeoxycorticosterone) is an endogenous neurosteroid (a steroid that acts rapidly on neuronal membrane receptors rather than on classical nuclear hormone receptors) and the fully reduced 3-alpha,5-alpha metabolite of the adrenal steroid deoxycorticosterone. It is one of the most potent naturally occurring positive allosteric modulators (compounds that amplify a receptor's response to its own transmitter) of the GABA-A receptor, the brain's principal inhibitory chloride ion channel, where it enhances both fast synaptic and sustained extrasynaptic inhibition. Because its synthesis is driven by adrenocorticotropic hormone and by acute stress, THDOC is regarded as a stress-responsive inhibitory neurosteroid that provides negative feedback on the hypothalamic-pituitary-adrenal axis and transiently raises the seizure threshold. Alongside allopregnanolone, it is a prototypical member of the stress-derived GABAergic neurosteroid family.